New Clinical Data Suggest Infusion Set with BD FlowSmart Technology May Improve Insulin Flow and Reduce Silent Occlusions

Studies Presented at the American Diabetes Association’s 75th Scientific Sessions Demonstrate Potential Benefits of Proprietary Side-Ported Catheter

Jun 6, 2015

BOSTON, MA, June 6, 2015 – BD Medical, a segment of leading global medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX), released research on infusion sets that represents a potential improvement in insulin pump therapy for people with diabetes. Three different posters will be presented at the American Diabetes Association’s annual meeting with data on a new insulin infusion set with BD FlowSmart technology. Infusion sets have been described as “the Achilles heel” of insulin pump therapy.i

The insulin infusion set with BD FlowSmart technology was developed in collaboration with JDRF and The Leona M. and Harry B. Helmsley Charitable Trust to enhance the use of insulin pumps and improve the treatment of type 1 diabetes. This infusion set recently received both FDA clearance and Health Canada approval and is expected to be launched in 2016. An application has been submitted for CE marking.

“Silent occlusions have recently been recognized as a potential factor for unexplained hyperglycemia in some people using insulin pumps.” said Laurence Hirsch, M.D., a study co-author and Worldwide Vice President of Medical Affairs, BD Medical-Diabetes Care. “They occur when there are interruptions to the flow of insulin from the pump to the body that do not trigger the pump occlusion alarm, leaving the pump user unaware of these lapses. Our research suggests that the BD infusion set can provide more consistent insulin delivery and may reduce the occurrence of silent occlusions, which is important news for insulin pump users.”

1071-P: Continuous Subcutaneous Insulin Infusion Sets: Reduced Flow Interruptions with a Novel Catheter Set – Study Details

In this novel human study, researchers conducted a head-to-head comparison of the BD infusion set and the leading commercially available infusion set, in 60 healthy subjects, who received two insertions of each infusion set followed by infusions of insulin diluent. The results showed that pressure rise events or silent occlusions were reduced by 75 percent, p = 0.03, from 10.2 percent to 2.6 percent of infusions. A silent occlusion is defined as a continuous rise in pressure of at least 30 minutes. Decreasing such flow interruptions may benefit patients by providing more consistent insulin delivery.

1088-P: Performance Qualification of Novel Continuous Subcutaneous Insulin Infusion Set Using Medical Imaging – Study Details

This study used medical imaging techniques including MRI for the first time, to evaluate infusion catheter placement and fluid delivery patterns at various subcutaneous infusion sites. Studies conducted in both animals and people without diabetes assessed the performance of the BD side-ported catheter and other commercially-available catheters in their placement and delivery of insulin or insulin diluent. The images showed that the side port provides an additional flow pathway that may reduce occlusions and stabilize insulin flow.

1085-P: In Vivo Flow Evaluation and Correlation to Insulin Pharmacokinetics of Continuous Subcutaneous Insulin Infusion Sets – Study Details

This study examined the flow performance of the BD infusion set compared with three commercial sets and their recommended pumps. The research, performed in non-diabetic Yorkshire swine, used flow pressure monitoring along with insulin-level analyses. The BD infusion set showed reductions of 88-95 percent in mean percent time of flow interruption as compared to the commercial catheter sets.

To register for more information, please visit www.bd.com/InfusionSet

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit bd.com

For more information on BD, please visit bd.com.

Lindsay Roman

201 847 4312
Email Lindsay

Back to News Releases



i Heinemann, L. and Krinelke, L. Insulin Infusion Set: The Achilles Heel of Continuous Subcutaneous Insulin Infusion. J Diabetes Sci Technol. 2012 Jul; 6(4): 954–964.